MedTrace Logo

Relative Effectiveness of Schizophrenia Therapy Study

NCT01245348 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1110

Last updated 2013-02-25

No results posted yet for this study

Summary

The purpose of this study is to validate that SULT4A1-1 status stratification improves responses to atypical antipsychotics in schizophrenia and to extend these findings into bipolar disorder.

Conditions

Interventions

GENETIC

SULT4A1-1 genetic test

SULT4A1-1 haplotype result (+/-)

Sponsors & Collaborators

  • SureGene, LLC

    collaborator INDUSTRY

  • Medco Health Solutions, Inc.

    lead INDUSTRY

Principal Investigators

  • Kelly Parsons, Ph.D. · Medco Health Solutions, Inc.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01245348 on ClinicalTrials.gov